137.75

6.70% 8.65

Axsome Therapeutics Inc (AXSM)

Overview News Price History Option Chain Financials Why AXSM Down? Discussions Forecast

Axsome Therapeutics Inc stock is traded at $137.75, with a volume of 1.48M. It is up +6.70% in the last 24 hours and up +43.22% over the past month. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Previous Close:

$129.10

Open:

$130.04

24h Volume:

1.48M

Relative Volume:

1.74

Market Cap:

$6.54B

Revenue:

$338.46M

Net Income/Loss:

$-310.96M

P/E Ratio:

-21.09

EPS:

-6.53

Net Cash Flow:

$-132.82M

1W Performance:

+5.03%

1M Performance:

+43.22%

6M Performance:

+56.69%

1Y Performance:

+67.76%

1-Day Range:

$128.38

$139.13

1-Week Range:

$124.03

$139.13

52-Week Range:

$64.11

$139.13

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name

Axsome Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

(212) 332-3241

Address

ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK

Employee

569

Twitter

Next Earnings Date

2025-02-18

Latest SEC Filings

AXSM's Discussions on Twitter

Compare AXSM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AXSM Axsome Therapeutics Inc	137.75	6.54B	338.46M	-310.96M	-132.82M	-6.53
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-31-24	Reiterated	Mizuho	Outperform
Sep-03-24	Initiated	Wells Fargo	Overweight
Aug-06-24	Upgrade	BofA Securities	Neutral → Buy
Jul-22-24	Initiated	Needham	Buy
Apr-29-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-19-24	Initiated	Robert W. Baird	Outperform
Feb-06-24	Initiated	UBS	Buy
Jan-25-24	Initiated	RBC Capital Mkts	Outperform
Dec-13-23	Initiated	Citigroup	Buy
Aug-08-23	Upgrade	BofA Securities	Underperform → Neutral
Jan-05-23	Initiated	Piper Sandler	Neutral
Nov-01-22	Initiated	Loop Capital	Buy
Sep-07-22	Resumed	Mizuho	Buy
Aug-10-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-10-21	Initiated	Berenberg	Buy
Jan-08-21	Initiated	Jefferies	Buy
Dec-16-20	Initiated	Mizuho	Buy
Sep-29-20	Initiated	BofA Securities	Underperform
Sep-10-20	Initiated	Morgan Stanley	Overweight
Apr-28-20	Reiterated	H.C. Wainwright	Buy
Apr-14-20	Initiated	Cowen	Outperform
Dec-30-19	Reiterated	H.C. Wainwright	Buy
Dec-17-19	Reiterated	H.C. Wainwright	Buy
Dec-16-19	Reiterated	Guggenheim	Buy
Oct-16-19	Initiated	Guggenheim	Buy
Sep-18-19	Initiated	William Blair	Outperform
May-28-19	Initiated	SunTrust	Buy
May-23-19	Reiterated	H.C. Wainwright	Buy
Apr-08-19	Initiated	SVB Leerink	Outperform
Mar-15-19	Reiterated	H.C. Wainwright	Buy
Oct-03-16	Resumed	Brean Capital	Buy
Dec-15-15	Initiated	Cantor Fitzgerald	Buy
Dec-14-15	Initiated	Ladenburg Thalmann	Buy

View All

Axsome Therapeutics Inc Stock (AXSM) Latest News

11:42 AM

Axsome Therapeutics (NASDAQ:AXSM) Hits New 52-Week High on Analyst Upgrade - MarketBeat

11:42 AM

09:10 AM

Axsome Therapeutics stock soars to all-time high of $134.2 By Investing.com - Investing.com Nigeria

Feb 21, 2025

Axsome Therapeutics (NASDAQ:AXSM) Issues Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat

Feb 21, 2025

Axsome Therapeutics stock soars to all-time high of $134.2 - Investing.com India

Feb 21, 2025

Axsome Therapeutics (NASDAQ:AXSM) Releases Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat

Feb 21, 2025

Astrazeneca, Vertex, Axsome secure US FDA approvals in January - BioWorld Online

Feb 21, 2025

Axsome Therapeutics targets multiple NDA submissions and pipeline advancements through 2025 - MSN

Feb 21, 2025

Mizuho maintains Axsome Outperform rating, $195 target - Investing.com

Feb 21, 2025

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $200.00 at HC Wainwright - MarketBeat

Feb 21, 2025

FY2028 Earnings Estimate for AXSM Issued By Leerink Partnrs - MarketBeat

Feb 21, 2025

Axsome Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks

Feb 21, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Peregrine Capital Management LLC - MarketBeat

Feb 21, 2025

Strategic Financial Concepts LLC Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Feb 21, 2025

Feb 20, 2025

Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration - AOL

Feb 20, 2025

Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride - MSN

Feb 20, 2025

Axsome Therapeutics (NASDAQ:AXSM) Receives Outperform Rating from William Blair - MarketBeat

Feb 20, 2025

Truist Financial Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat

Feb 20, 2025

Cantor Fitzgerald Reaffirms Overweight Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat

Feb 20, 2025

Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering (NASDAQ:AXSM) - Seeking Alpha

Feb 20, 2025

Needham & Company LLC Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat

Feb 20, 2025

Axsome Therapeutics Revenue Surges 66% - MSN

Feb 20, 2025